{
    "organizations": [],
    "uuid": "6d7ffedf6adbfb304fe1d2db21f62a1d4df98f25",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/idUSL5N1SN1SK",
    "ord_in_thread": 0,
    "title": "BRIEF-Celyad Says Grade 4 Adverse Events Occurred In Two THINK Trial Patients, Announces Q1 Business Update",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 16 (Reuters) - CELYAD SA:\n* ANNOUNCED ON TUESDAY Q1 BUSINESS AND THINK TRIAL UPDATES * GRADE 4 SERIOUS ADVERSE EVENTS OCCURRED IN TWO PATIENTS OF CYAD-01 THINK TRIAL OUT OF 20 PATIENTS INCLUDED IN INTERIM SAFETY REPORT\n* THOSE TWO PATIENTS EACH EXPERIENCED A GRADE 5 EVENT THAT WAS DEEMED UNRELATED TO ADMINISTRATION\n* CYAD-01 IS CURRENTLY BEING EVALUATED AS A STAND-ALONE INVESTIGATIONAL THERAPY IN THE THINK TRIAL WITH RELAPSED REFRACTORY AML AND CRC PATIENTS\n* CYAD-01 IS ALSO BEING EVALUATED FOR BEING ADMINISTERED AFTER LYMPHODEPLETION PRECONDITIONING - RELEVANT DEPLETHINK AML AND CRC TRIALS TO BE INITIATED IN COMING WEEKS\n* IN MAY 2018, ACHIEVED IMPORTANT MILESTONE IN ITS CYAD-01 CLINICAL STRATEGY BY DOSING FIRST METASTATIC CRC PATIENTS IN THE LINK AND SHRINK TRIALS\n* NO DRUG RELATED TOXICITY WAS OBSERVED IN THE FIRST PATIENTS OF BOTH SHRINK AND LINK TRIALS\n* ENDED Q1 WITH EUR 25.1 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS\n* CONFIRMS EXISTING CASH AND CASH EQUIVALENTS AND SHORT TERM INVESTMENTS ARE SUFFICIENT TO FUND EXPENSES UNTIL END-Q1 2019\nSource text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-05-16T15:31:00.000+03:00",
    "crawled": "2018-05-17T14:36:20.060+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "celyad",
        "sa",
        "announced",
        "tuesday",
        "q1",
        "business",
        "think",
        "trial",
        "update",
        "grade",
        "serious",
        "adverse",
        "event",
        "occurred",
        "two",
        "patient",
        "think",
        "trial",
        "patient",
        "included",
        "interim",
        "safety",
        "report",
        "two",
        "patient",
        "experienced",
        "grade",
        "event",
        "deemed",
        "unrelated",
        "administration",
        "currently",
        "evaluated",
        "investigational",
        "therapy",
        "think",
        "trial",
        "relapsed",
        "refractory",
        "aml",
        "crc",
        "patient",
        "also",
        "evaluated",
        "administered",
        "lymphodepletion",
        "preconditioning",
        "relevant",
        "deplethink",
        "aml",
        "crc",
        "trial",
        "initiated",
        "coming",
        "week",
        "may",
        "achieved",
        "important",
        "milestone",
        "clinical",
        "strategy",
        "dosing",
        "first",
        "metastatic",
        "crc",
        "patient",
        "link",
        "shrink",
        "trial",
        "drug",
        "related",
        "toxicity",
        "observed",
        "first",
        "patient",
        "shrink",
        "link",
        "trial",
        "ended",
        "q1",
        "eur",
        "million",
        "cash",
        "cash",
        "equivalent",
        "investment",
        "confirms",
        "existing",
        "cash",
        "cash",
        "equivalent",
        "short",
        "term",
        "investment",
        "sufficient",
        "fund",
        "expense",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}